Anticoagulation after Transcatheter Aortic Valve Implantation: Current Status

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Transcatheter aortic valve implantation (TAVI) is a standard treatment for severe aortic stenosis.
• Antithrombotic therapy is crucial post-TAVI to prevent thrombotic events.
• Current guidelines lack strong evidence, necessitating further research into optimal antithrombotic strategies.

Purpose of the Study:

• To critically evaluate the influence of antithrombotic medications, particularly anticoagulants.
• To assess the long-term clinical outcomes in patients following TAVI.
• To inform the development of evidence-based antithrombotic regimens.

Main Methods:

• Literature review of existing studies and clinical trials.
• Analysis of data concerning antithrombotic drug efficacy and safety.
• Exploration of the balance between thrombotic prevention and bleeding risk.

Main Results:

• Antithrombotic therapy presents a dual risk of thrombosis and bleeding post-TAVI.
• The optimal choice and duration of antithrombotic treatment remain under investigation.
• Ongoing randomized controlled trials are expected to provide definitive evidence.

Conclusions:

• The optimal antithrombotic strategy after TAVI is not yet established.
• Balancing the benefits and risks of antithrombotic therapy is critical for patient outcomes.
• Further research is essential to guide clinical practice and improve patient care.